Our dedicated patient engagement team, comprising Chris Dodd, Erik Farish, and Sairah Yassir-Deane, had an enriching experience at the ‘Management in Practice’ event in Manchester. We had the opportunity to interact with numerous General Practitioners (GPs) from across the UK, who are keen to introduce the concept of patient engagement in clinical research to their …
Panthera finds quality patients fast Since its launch in 2019 Panthera has concentrated on building access to patients. Today Panthera has not only access to the largest qualified patient pool in the UK – NHS or SMO – but has also built a network of GP practices including some of the leading mega GP practices providing …
Lord James O’Shaughnessy, former Health Minister, has been appointed by the UK government to conduct an independent review of the country’s commercial clinical trials landscape. The review will advise on how to resolve key challenges in conducting commercial clinical trials and ensure that the UK remains a global leader in the field. Lord O’Shaughnessy’s advice is expected to be published this spring.
Dr Ian Smith (Co-founder, Director and Chief Medical Officer) and Chris Dodd (Chief Commercial Officer) recently spoke to Jo Shorthouse at In Vivo to discuss the practicalities and reality of running clinical trial sites as a business, the efficiencies found with the SMO model, the challenge of patient recruitment as well as the decentralized and hybridized trial model. To listen to the …
The independent Site Management Organisations (SMOs) which run clinical trials on behalf of the pharmaceutical industry continue to expand not only the number of trials being brought to the UK but also the number of patients enrolled.
New data show that the site management model reduces start-up times for a Phase II or Phase III clinical trial by up to nine months compared to UK public sites, representing billions in savings Panthera identifies likely patients seven months before public sector sites start planning their recruitment campaigns. The loss of nine months patent …
Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …
Panthera have formed a partnership with Preston North End Football Club Community Trust. The team at Panthera attended the PNE vs Birmingham City game on the 15th of January promoting clinical trials. Fans who visited the Panthera van on game day also learnt more about additional clinical trials, such as those aimed at combating Osteoarthritis and Cardiovascular …
Valneva have released results from their phase 3 vaccine study (VLA2001). Stating that the trial has successfully met both co-primary end points. This trial compared the efficacy and effectiveness of the Valneva Covid-19 vaccine against the AstraZeneca vaccine. A total of 4012 people, aged 18 years and above were recruited to this clinical trial, across …
This month we have been busy vaccinating volunteers in North Manchester, Preston and North London for a new COVID prevention study. It has been an exciting time as we were the world’s first clinical trial site to administer the vaccine to volunteers in this study. The first participant to be vaccinated at our Rochdale clinic …
